Related Experiment Video

Updated: Aug 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results

Luis Miguel Blanco-Colio1, Julio I Osende, Jose Luis Martín-Ventura

  • 1Vascular Research Laboratory, Fundación Jiménez Diaz, Autonoma University, Madrid, Spain.

Drugs
|March 16, 2005
PubMed

Insights

Statins like atorvastatin benefit hypertensive patients by lowering lipids and through other mechanisms. These effects, including inhibition of isoprenoid synthesis, impact cell signaling pathways crucial for cardiovascular health.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Molecular Biology

Background:

  • The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) investigated statin use in hypertensive patients.
  • Hypertensive patients often have average cholesterol levels but other cardiovascular risk factors.
  • Statins demonstrate clinical benefits beyond lipid reduction in this population.

Purpose of the Study:

  • To explore the lipid-dependent and lipid-independent effects of atorvastatin in hypertensive patients.
  • To summarize statin's multifaceted actions in relation to ASCOT-LLA findings.
  • To highlight the role of isoprenoid synthesis inhibition in statin's mechanism of action.

Main Methods:

  • Analysis of data from the ASCOT-LLA study.
  • Review of scientific literature on statin mechanisms.
  • Focus on isoprenoid synthesis inhibition and its downstream effects.

Main Results:

  • Atorvastatin provides clinical benefits in hypertensive patients with average cholesterol.
  • These benefits are attributed to both lipid-lowering and non-lipid-lowering effects.
  • Inhibition of isoprenoid synthesis is a key mechanism, affecting intracellular signaling proteins.

Conclusions:

  • Statins, exemplified by atorvastatin, offer significant cardiovascular protection in hypertensive individuals.
  • The therapeutic effects involve complex interactions with cellular processes via isoprenoid pathway modulation.
  • Understanding these mechanisms enhances the application of statins in cardiovascular risk management.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...